Background: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japa http://t.co/dxs8fsZ17j
via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/dxs8fsZ17j
via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/dxs8fsZ17j
No comments:
Post a Comment